← The Wire
NUVLNasdaq
Nuvalent, Inc.
Pharmaceutical Preparations · DE · CIK 1861560
Nuvalent creates precisely targeted small molecule therapies for cancer patients, aiming to overcome limitations of existing treatments
🔥 High media attention
$9.75B
Market cap
$123.51
Last close
-0.0%
1D
+0.1%
5D
1.3M
Volume
Price · last 39 sessions+20.4%
May 4L $88.49 · H $123.58Jun 29
108
Total filings
Jun 18, 2026
Last filing
12/31
Fiscal year end
DEF 14ADEF 14AApr 28, 2026DEF 14ADEF 14AApr 28, 2025DEF 14ADEF 14AApr 26, 2024DEF 14ADEF 14AApr 28, 2023DEF 14ADEF 14AApr 29, 2022
Insider Activity
In the 90 days to Mar 26, 2026: 6 sold $20.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 26, 2026 | Miller Deborah AnnChief Legal Officer | Sell | 2,803 | $99.46 | $279K |
| Mar 26, 2026 | Miller Deborah AnnChief Legal Officer | Sell | 1,757 | $98.21 | $173K |
| Mar 26, 2026 | Miller Deborah AnnChief Legal Officer | Sell | 940 | $97.50 | $92K |
| Mar 25, 2026 | Balcom AlexandraChief Financial Officer | Sell | 13,700 | $100.16 | $1.4M |
| Mar 24, 2026 | Balcom AlexandraChief Financial Officer | Sell | 7,671 | $95.88 | $735K |
| Mar 24, 2026 | Balcom AlexandraChief Financial Officer | Sell | 2,599 | $95.03 | $247K |
| Mar 24, 2026 | Balcom AlexandraChief Financial Officer | Sell | 1,160 | $96.50 | $112K |
| Mar 13, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 2,597 | $98.83 | $257K |
| Mar 13, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 1,703 | $99.71 | $170K |
| Mar 13, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 804 | $97.89 | $79K |
| Mar 12, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 24,189 | $97.79 | $2.4M |
| Mar 12, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 5,505 | $98.44 | $542K |
| Mar 12, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 306 | $99.12 | $30K |
| Mar 6, 2026 | Porter James RichardPresident and CEO | Sell | 16,015 | $99.29 | $1.6M |
| Mar 6, 2026 | Porter James RichardPresident and CEO | Sell | 13,585 | $98.59 | $1.3M |
| Mar 6, 2026 | Porter James RichardPresident and CEO | Sell | 400 | $100.19 | $40K |
| Feb 26, 2026 | Noci DarleneChief Development Officer | Sell | 3,000 | $102.64 | $308K |
| Feb 26, 2026 | Miller Deborah AnnChief Legal Officer | Sell | 2,698 | $102.64 | $277K |
| Feb 26, 2026 | Miller Deborah AnnChief Legal Officer | Sell | 2,602 | $103.41 | $269K |
| Feb 26, 2026 | Noci DarleneChief Development Officer | Sell | 2,300 | $103.44 | $238K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 8 reputable articles · skews ▲ positive.
ReutersGSK boosts cancer portfolio with $10.6 billion Nuvalent takeover20d agoInvestor's Business DailySmall Biotech Catapults To Record High On $10.6 Billion Deal20d agoReutersUK's FTSE 100 hits over three-week low as banks, energy stocks sag20d agoBloomberg.comUS Premarket Movers for June 9, 202621d agoCNBCStocks making the biggest moves premarket: GSK, Nuvalent, J.M. Smucker, SailPoint and more21d agoWSJGSK to Buy Nuvalent for $10.6 Billion in Oncology Push21d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance